Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Phase 3 readiness activities are underway while formal FDA feedback on the proposed pivotal program remains pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Radiopharm Theranostics (RADX) completed an End-of-Phase 2 meeting with the FDA regarding pivotal development of RAD101 for brain metastases imaging. Previously reported Phase 2b results showed 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint.
The company expects official FDA minutes within approximately 30 days and plans an update after reviewing them. It is advancing Phase 3 clinical and operational planning while awaiting formal feedback on the proposed program. RAD101 has FDA Fast Track Designation to distinguish recurrent disease from treatment effects in brain metastases from solid tumors, including leptomeningeal disease. A recently announced Siemens Healthineers partnership will provide manufacturing and distribution of RAD101 doses for the upcoming U.S. Phase 3 registrational trial. Radiopharm is also evaluating opportunities to engage potential strategic partners.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point93% concordance with MRI across all evaluable lesions met the Phase 2 trial's primary endpoint.
- Moderate pointFDA End-of-Phase 2 meeting completed for RAD101's proposed pivotal development program.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Siemens Healthineers partnership will manufacture and distribute RAD101 doses for the upcoming U.S. Phase 3 registrational trial.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 3 readiness activities are advancing through clinical and operational planning.
- Minor pointFDA Fast Track Designation covers distinguishing recurrent disease from treatment effects in brain metastases, including leptomeningeal disease.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential strategic partner engagement is being evaluated by Radiopharm.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Formal FDA feedback remains pending; official meeting minutes are expected within approximately 30 days.
Key Figures
- MRI concordance
- 93%
- Phase 2b trial; across all evaluable lesions, meeting the primary endpoint
- FDA meeting minutes
- approximately 30 days
- Expected timing for receipt of the official meeting minutes
Previous Clinical trial Reports
-
Phase 2b data met the primary endpoint at 93% concordance, and an FDA meeting was planned.
-
Company scheduled an End-of-Phase 2 meeting to align on RAD101 pivotal Phase 3 design.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
end-of-phase 2 regulatory
fatty acid synthase (fasn) medical
fast track designation regulatory
pet-mri technical
leptomeningeal disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging
Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days
SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage radiopharmaceutical company, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA or the Agency) regarding RAD101, the Company's investigational radiopharmaceutical imaging agent for the detection of brain metastases.
RAD101 is the Company's novel Fluorine-18-labeled small-molecule imaging agent that targets fatty acid synthase (FASN) and is being developed to diagnose suspected recurrent brain metastases arising from a range of solid tumors. Previously reported data from the Phase 2b clinical trial showed that RAD101 demonstrated
The Company expects to receive the FDA's official meeting minutes within approximately 30 days. The minutes will provide the formal record of the meeting and the Agency's feedback on the proposed pivotal clinical development program. RAD intends to provide a further update following receipt and review of the official minutes.
“The successful completion of our End-of-Phase 2 meeting with the FDA marks a pivotal milestone for RAD101 and an important inflection point in the evolution of our company,” said Riccardo Canevari, Chief Executive Officer of Radiopharm. “The discussion was highly constructive and provided meaningful clarity on the regulatory pathway for RAD101, reinforcing our confidence in the program's potential to address a significant unmet need in brain metastases imaging. We are encouraged by the collaborative dialogue with the Agency and believe this interaction positions us well as we finalize our pivotal development strategy and take the next critical steps toward a potential registration program.”
Building on the momentum from the meeting, RAD is moving immediately to advance Phase 3 readiness activities, including clinical and operational planning, in order that the program is positioned to progress efficiently once the Agency's formal feedback is received.
“RAD101 represents a differentiated imaging approach targeting fatty acid synthase, a compelling biological mechanism that has demonstrated promising clinical potential in brain metastases,” continued Mr. Canevari. “As we prepare for pivotal development, we are also evaluating opportunities to engage with potential strategic partners who recognize the value of this program and share our vision for bringing this innovation to patients and clinicians worldwide. Given the scale of the opportunity and the maturity of the asset, we believe now is the appropriate time to explore pathways that could maximize both clinical impact and long-term value creation.”
RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company also recently announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support Radiopharm’s upcoming Phase 3 registrational trial in the U.S.
In the U.S. alone, there are more than 300,000 patients diagnosed annually with cerebral metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the Primary tumor. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimize patient care.1
About RAD101
RAD101 is the Company’s novel imaging small molecule that selectively binds to fatty acid synthase (FASN), a multi-enzyme protein that catalyses de-novo fatty acid synthesis and is overexpressed in cerebral metastasis from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College of London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival, warranting larger studies.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. Learn more at radiopharmtheranostics.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements regarding the planned development of RAD101, potential future clinical trials, regulatory interactions, Phase 3 readiness activities, a potential NDA submission, and potential strategic partnering opportunities. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. RAD101 is an investigational product and has not been approved for commercial use by the FDA or any other regulatory authority.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Radiopharm's RAD101 Phase 2b trial show?
Previously reported Phase 2b data showed 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint.
What happens next after Radiopharm's RAD101 FDA meeting?
Radiopharm expects official FDA meeting minutes within approximately 30 days and intends to provide an update after receiving and reviewing them. The minutes will formally record the meeting and the FDA's feedback on the proposed pivotal program. Phase 3 clinical and operational planning is already underway.